KR20230145360A - 4-아미노퀴나졸린 화합물 - Google Patents

4-아미노퀴나졸린 화합물 Download PDF

Info

Publication number
KR20230145360A
KR20230145360A KR1020237027664A KR20237027664A KR20230145360A KR 20230145360 A KR20230145360 A KR 20230145360A KR 1020237027664 A KR1020237027664 A KR 1020237027664A KR 20237027664 A KR20237027664 A KR 20237027664A KR 20230145360 A KR20230145360 A KR 20230145360A
Authority
KR
South Korea
Prior art keywords
methyl
cyclopropyl
oxy
compound
diazabicyclo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237027664A
Other languages
English (en)
Korean (ko)
Inventor
겐이치 가와구치
가즈유키 구라모토
도모요시 이마이즈미
다카히로 모리카와
미츠아키 오쿠무라
스나오 이마다
에이지 가와미나미
료 사토
요헤이 세키
히사오 하마구치
히로키 이시오카
히로키 후쿠도메
이쿠미 구리와키
다케유키 나가시마
Original Assignee
아스텔라스세이야쿠 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아스텔라스세이야쿠 가부시키가이샤 filed Critical 아스텔라스세이야쿠 가부시키가이샤
Publication of KR20230145360A publication Critical patent/KR20230145360A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020237027664A 2021-02-15 2022-02-14 4-아미노퀴나졸린 화합물 Pending KR20230145360A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JPJP-P-2021-021684 2021-02-15
JP2021021684 2021-02-15
PCT/JP2022/005583 WO2022173033A1 (ja) 2021-02-15 2022-02-14 ４－アミノキナゾリン化合物

Publications (1)

Publication Number Publication Date
KR20230145360A true KR20230145360A (ko) 2023-10-17

Family

ID=82838845

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237027664A Pending KR20230145360A (ko) 2021-02-15 2022-02-14 4-아미노퀴나졸린 화합물

Country Status (12)

Country Link
US (1) US20240150366A1 (https=)
EP (1) EP4293025B1 (https=)
JP (1) JP7725511B2 (https=)
KR (1) KR20230145360A (https=)
CN (1) CN116867788A (https=)
AU (1) AU2022219651A1 (https=)
CA (1) CA3211110A1 (https=)
ES (1) ES3054794T3 (https=)
MX (1) MX2023009520A (https=)
PL (1) PL4293025T3 (https=)
SA (1) SA523450286B1 (https=)
WO (1) WO2022173033A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2024008849A (es) 2022-01-21 2024-07-25 Usynova Pharmaceuticals Ltd Compuestos de benzopirimidina y uso de estos.
AU2023231912A1 (en) * 2022-03-11 2024-08-15 Astellas Pharma Inc. Heterocyclic compound for inducing degradation of g12d mutant kras protein
JP7733274B1 (ja) * 2022-08-12 2025-09-02 アステラス製薬株式会社 Ｇ１２ｄ変異ｋｒａｓ阻害活性を有する二官能性化合物を含む抗がん剤の組合せ
AR130192A1 (es) * 2022-08-12 2024-11-13 Astellas Pharma Inc Combinaciones antineoplásicas que comprenden quimioterapia
WO2024188281A1 (zh) * 2023-03-13 2024-09-19 南京明德新药研发有限公司 含喹唑啉结构的化合物及其应用
AU2024337913A1 (en) 2023-09-08 2026-03-26 Gilead Sciences, Inc. Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
WO2025052649A1 (ja) * 2023-09-08 2025-03-13 アステラス製薬株式会社 単一の軸不斉化合物の選択的製造法
US20250114339A1 (en) 2023-10-09 2025-04-10 Incyte Corporation Combination therapy comprising a kras g12d inhibitor and an egfr inhibitor
AU2024357850A1 (en) 2023-10-09 2026-04-23 Incyte Corporation Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016049568A1 (en) 2014-09-25 2016-03-31 Araxes Pharma Llc Methods and compositions for inhibition of ras
WO2016049565A1 (en) 2014-09-25 2016-03-31 Araxes Pharma Llc Compositions and methods for inhibition of ras
WO2017172979A1 (en) 2016-03-30 2017-10-05 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
WO2021041671A1 (en) 2019-08-29 2021-03-04 Mirati Therapeutics, Inc. Kras g12d inhibitors
WO2021107160A1 (en) 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190186A1 (ar) * 2017-02-02 2019-08-01 Astellas Pharma Inc مركب كينازولين
US20220363681A1 (en) * 2019-08-16 2022-11-17 Genfleet Therapeutics (Shanghai) Inc. Oxo six-membered cyclopyrimidine compound, preparation method and medical use thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016049568A1 (en) 2014-09-25 2016-03-31 Araxes Pharma Llc Methods and compositions for inhibition of ras
WO2016049565A1 (en) 2014-09-25 2016-03-31 Araxes Pharma Llc Compositions and methods for inhibition of ras
WO2017172979A1 (en) 2016-03-30 2017-10-05 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
WO2021041671A1 (en) 2019-08-29 2021-03-04 Mirati Therapeutics, Inc. Kras g12d inhibitors
WO2021107160A1 (en) 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation
WO2021106231A1 (en) 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation

Also Published As

Publication number Publication date
EP4293025A4 (en) 2025-02-26
SA523450286B1 (ar) 2024-06-12
AU2022219651A1 (en) 2023-09-07
US20240150366A1 (en) 2024-05-09
MX2023009520A (es) 2023-08-24
EP4293025B1 (en) 2025-10-29
JP7725511B2 (ja) 2025-08-19
EP4293025C0 (en) 2025-10-29
JPWO2022173033A1 (https=) 2022-08-18
PL4293025T3 (pl) 2026-02-16
WO2022173033A1 (ja) 2022-08-18
EP4293025A1 (en) 2023-12-20
CA3211110A1 (en) 2022-08-18
CN116867788A (zh) 2023-10-10
ES3054794T3 (en) 2026-02-06

Similar Documents

Publication Publication Date Title
JP7725511B2 (ja) ４－アミノキナゾリン化合物
JP7440710B1 (ja) Ｇ１２ｄ変異ｋｒａｓタンパクに作用する複素環化合物
JP7169729B1 (ja) Ｇ１２ｄ変異ｋｒａｓタンパクの分解を誘導するためのキナゾリン化合物
JP6587116B2 (ja) キナゾリン化合物
CA3255513A1 (en) HETEROCYCLIC COMPOUND TO INDUCE DETERIORATION OF G12D MUTATION KRAS PROTEIN
WO2022037568A1 (en) Bicyclic compounds, compositions and use thereof
WO2024034591A1 (ja) Ｋｒａｓタンパクを阻害及び／又は分解誘導するための複素環化合物
WO2024067714A1 (zh) 具有抗kras突变肿瘤活性的化合物
CN111936499A (zh) Mat2a的杂二环抑制剂和用于治疗癌症的方法
US9181264B2 (en) Fused heteroaryls and their uses
JP2022542396A (ja) Ｃｄ３８の阻害剤としてのヘテロ二環式アミド
TW202525817A (zh) 三𠯤化合物
TWI785474B (zh) 用作選擇性Aurora A抑制劑的新型雜環化合物
TW201305160A (zh) 作為新的ＳｙＫ抑制劑的取代的吡啶并吡嗪化合物
KR20180030545A (ko) 바이사이클릭 헤테로사이클릭 아미드 유도체
JP7724392B1 (ja) Ｋｒａｓタンパクの分解を誘導するための複素環化合物
CN103124731A (zh) 稠合的杂芳基化合物及其应用
CN115873000A (zh) 异喹啉酮类及喹唑啉酮类化合物及其组合物和用途
CN115894497A (zh) 一类咪唑并嘧啶化合物、其制备方法及用途
TW202237101A (zh) Ｃｔｌａ－４小分子降解劑及其應用
CN119053596A (zh) 作为激酶抑制剂的杂环化合物、其组合物及使用方法
JP7851842B2 (ja) Ｇ１２ｄ変異ｋｒａｓタンパクの分解を誘導するためのキナゾリン化合物
KR102958021B1 (ko) 피리다지닐 티아졸카르복시아미드 화합물
HK40096919A (zh) 用於诱导g12d突变kras蛋白分解的喹唑啉化合物

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230816

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250203

Comment text: Request for Examination of Application